- Expires: December 28, 2022
- Credit: 1.00hr(s)
- CME
- Therapeutic Areas: Oncology, Urologic oncology
- Specialties: urothelial carcinoma (UC)
Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors.